The GP2 peptide: A HER2/neu-based breast cancer vaccine

Kevin S. Clive; Josh A. Tyler; G. Travis Clifton; Jarrod P. Holmes; Sathibalan Ponniah; George E. Peoples; Elizabeth A. Mittendorf

doi:10.1002/jso.21723

The GP2 peptide: A HER2/neu-based breast cancer vaccine

Kevin S. Clive
, Josh A. Tyler
, G. Travis Clifton
, Jarrod P. Holmes
, Sathibalan Ponniah
, George E. Peoples
, Elizabeth A. Mittendorf

Research output: Contribution to journal › Review article › peer-review

40 Scopus citations

Abstract

Preclinical studies suggest that GP2, a HER2/neu-derived peptide, is immunogenic. Subsequent phase I clinical trials demonstrated that GP2-based vaccines are safe and effective in stimulating peptide-specific immunity. A GP2 peptide vaccine is currently being evaluated in a phase II efficacy trial enrolling breast cancer patients. This article reviews initial studies characterizing GP2, clinical trials investigating GP2-based vaccines, and novel immunotherapy strategies incorporating GP2 in combination with other peptides or with the monoclonal antibody trastuzumab.

Original language	English
Pages (from-to)	452-458
Number of pages	7
Journal	Journal of Surgical Oncology
Volume	105
Issue number	5
DOIs	https://doi.org/10.1002/jso.21723
State	Published - Apr 1 2012

Keywords

GP2
HER2/neu
cancer
immunotherapy
vaccine

Access to Document

10.1002/jso.21723

Cite this

@article{1ceb2a11ce48473abf01b5854284af97,

title = "The GP2 peptide: A HER2/neu-based breast cancer vaccine",

abstract = "Preclinical studies suggest that GP2, a HER2/neu-derived peptide, is immunogenic. Subsequent phase I clinical trials demonstrated that GP2-based vaccines are safe and effective in stimulating peptide-specific immunity. A GP2 peptide vaccine is currently being evaluated in a phase II efficacy trial enrolling breast cancer patients. This article reviews initial studies characterizing GP2, clinical trials investigating GP2-based vaccines, and novel immunotherapy strategies incorporating GP2 in combination with other peptides or with the monoclonal antibody trastuzumab.",

keywords = "GP2, HER2/neu, cancer, immunotherapy, vaccine",

author = "Clive, \{Kevin S.\} and Tyler, \{Josh A.\} and Clifton, \{G. Travis\} and Holmes, \{Jarrod P.\} and Sathibalan Ponniah and Peoples, \{George E.\} and Mittendorf, \{Elizabeth A.\}",

year = "2012",

month = apr,

day = "1",

doi = "10.1002/jso.21723",

language = "English",

volume = "105",

pages = "452--458",

journal = "Journal of Surgical Oncology",

issn = "0022-4790",

publisher = "Wiley-Liss Inc.",

number = "5",

}

TY - JOUR

T1 - The GP2 peptide

T2 - A HER2/neu-based breast cancer vaccine

AU - Clive, Kevin S.

AU - Tyler, Josh A.

AU - Clifton, G. Travis

AU - Holmes, Jarrod P.

AU - Ponniah, Sathibalan

AU - Peoples, George E.

AU - Mittendorf, Elizabeth A.

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Preclinical studies suggest that GP2, a HER2/neu-derived peptide, is immunogenic. Subsequent phase I clinical trials demonstrated that GP2-based vaccines are safe and effective in stimulating peptide-specific immunity. A GP2 peptide vaccine is currently being evaluated in a phase II efficacy trial enrolling breast cancer patients. This article reviews initial studies characterizing GP2, clinical trials investigating GP2-based vaccines, and novel immunotherapy strategies incorporating GP2 in combination with other peptides or with the monoclonal antibody trastuzumab.

AB - Preclinical studies suggest that GP2, a HER2/neu-derived peptide, is immunogenic. Subsequent phase I clinical trials demonstrated that GP2-based vaccines are safe and effective in stimulating peptide-specific immunity. A GP2 peptide vaccine is currently being evaluated in a phase II efficacy trial enrolling breast cancer patients. This article reviews initial studies characterizing GP2, clinical trials investigating GP2-based vaccines, and novel immunotherapy strategies incorporating GP2 in combination with other peptides or with the monoclonal antibody trastuzumab.

KW - GP2

KW - HER2/neu

KW - cancer

KW - immunotherapy

KW - vaccine

UR - https://www.scopus.com/pages/publications/84859018209

U2 - 10.1002/jso.21723

DO - 10.1002/jso.21723

M3 - Review article

C2 - 22441896

AN - SCOPUS:84859018209

SN - 0022-4790

VL - 105

SP - 452

EP - 458

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

IS - 5

ER -

The GP2 peptide: A HER2/neu-based breast cancer vaccine

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this